2025年欧洲血液学会年会（EHA 2025）已于6月12日至15日在意大利米兰圆满召开。作为EHA三十周年的重要里程碑，本届大会凭借强大的国际影响力及多项重磅科研成果，吸引了来自全球逾15,000名专家学者共襄盛举。大会期间，《肿瘤瞭望-血液时讯》特邀本届大会科学项目委员会（SPC）主席、德国慕尼黑大学Martin Dreyling教授接受采访，请他带领我们一览大会最具转折性的科研亮点。

Martin Dreyling教授：欢迎来到2025年欧洲血液学会年会（EHA 2025），这是EHA的第30届盛会。作为本届大会科学项目委员会（SPC）主席，我非常荣幸在这里与大家共襄盛举。
 

EHA年会的影响早已超越欧洲，成为全球血液学界的重要交流平台。今年，会议吸引了来自全球超过15,000名参会者，这充分体现了科学合作的力量。正如本次大会的核心宗旨：展示最新研究成果，促进深度交流，共同规划血液疾病诊疗的未来方向。
 

那么，EHA 2025有哪些值得关注的亮点？事实上，会议内容极其丰富，覆盖多个前沿领域，其中不少研究成果具有改变临床实践的潜力。也正因此，当大家下周一回到临床岗位时，或将开始重新思考治疗策略。

首先值得强调的是，本次大会的高质量研究来自全球多个国家和地区——不仅有来自美国的持续贡献，也有令人瞩目的亚洲声音。例如，中国学者在全体大会、LBA（Latest Breakthrough Abstract）和多个专题环节中均有重要成果展示，这一趋势令人振奋。

我们不妨从多发性骨髓瘤（MM）领域说起。今年的焦点依然是免疫治疗。虽然CAR-T细胞疗法在复发/难治性MM中已逐渐成为标准治疗手段，但新的组合策略正在持续推动疗效上限。例如，玛贝兰妥单抗（Belantamab）通过与其他靶向药物联用，正在“重获新生”，为无法接受细胞治疗的患者提供了可行的B计划。

此外，针对BCMA靶点的CAR-T疗法也正不断优化。会议公布了一种三特异性CAR-T细胞构建体，在早期研究中实现100%的应答率，且耐受性良好，显示出令人瞩目的潜力。与此同时，靶向不同表位的双特异性抗体疗法也表现优异，在LBA中披露的研究结果显示，其疗效几乎可媲美CAR-T，并具备更广泛的可及性。这些疗法将逐步改变复发性MM的治疗格局，开启真正意义上的“免疫治疗时代”。

在急性髓系白血病（AML）领域，Menin抑制剂成为另一个聚焦点。这些已进入临床的靶向药物，正在逐步替代传统高强度化疗，推动AML治疗迈向“精准靶向”阶段，真正改变我们对AML住院治疗的传统观念。
 

至于淋巴瘤，免疫治疗同样是关键词之一。今年的研究聚焦在一线治疗方案的优化。例如，双特异性抗体联合R-CHOP，或采用抗体偶联药物（ADC）替代标准化疗，均在II期研究中获得积极结果，我们期待其在III期研究中得到进一步验证。

而另一项“重磅突破”来自全体会议首次公布的III期研究结果：该研究将Pola-R-GEMOX（一种含维泊妥珠单抗的联合方案）与传统R-GEMOX进行了比较。在复发性DLBCL患者中，Pola-R-GEMOX显著提升了完全缓解率（提高约20%）、无进展生存期（提升15%-20%），并带来总生存期的延长。这不仅是疗效上的进步，更可能改写复发性DLBCL的标准治疗路径。对于下一位复发的DLBCL患者，这项方案或可作为CAR-T之外的重要治疗选择。

感谢大家的关注，来自米兰的问候，祝大家在本届大会有所收获！

Professor Martin Dreyling：Welcome to the 30th Annual Congress of the European Hematology Association (EHA 2025). I'm very pleased to welcome you all, and it's truly an honor for me to serve as this year’s Congress President.

The EHA Congress has long expanded beyond the geographical boundaries of Europe. This year, we are proud to host over 15,000 participants from around the globe, highlighting the power of scientific collaboration. Together, we can achieve far more than we ever could individually. This meeting embodies that spirit—sharing the latest data and fostering meaningful exchanges to shape the future of hematology care.

So, what are the highlights of EHA 2025? In fact, there’s a broad range of exciting developments, many of which are potentially practice-changing. When you return to your clinical work on Monday morning, you might find yourself rethinking some treatment decisions. Let me briefly touch on a few key areas.

First, it’s reassuring to see that high-quality research is coming from all over the world. While the U.S. continues to contribute important findings, I’d particularly like to highlight impactful data from Asia—especially China—which were featured in plenary sessions, late-breaking abstracts (LBAs), and disease-specific highlights. This reflects a growing global contribution to cutting-edge hematology research.

Let’s begin with multiple myeloma (MM). Immunotherapy remains the focal point. While CAR-T cell therapy has become standard for relapsed/refractory MM, the field continues to evolve rapidly—MM truly is the high-speed train of clinical research. Just two days ago, EHA released updated guidelines on MM, which I encourage you to review.
 

Notably, Belantamab mafodotin is experiencing a resurgence—not as a monotherapy, but in combination with other targeted agents. This provides a valuable “Plan B” for patients ineligible for cell therapy.

Building on existing BCMA-targeted CAR-T therapies, we’re now exploring combination strategies to enhance efficacy and prevent resistance. This year’s plenary and LBA sessions presented two remarkable approaches: one featured a tri-specific CAR-T cell construct, targeting two different epitopes, which achieved a 100% response rate—an extraordinary outcome, with manageable tolerability. These types of multi-targeted therapies are likely to shape the future of MM treatment.

Although these tri-specific CAR-T therapies are not yet commercially available, bispecific antibodies targeting multiple epitopes are already accessible. A combination study presented in the LBA session demonstrated exceptional response rates, nearly matching those of CAR-T, including high complete response (CR) rates. The question arises—are these therapies ready for prime time? The answer is a resounding yes, provided they’re available in your practice.

Turning to acute myeloid leukemia (AML), menin inhibitors have emerged as transformative agents. No longer “newcomers,” these targeted therapies are redefining AML treatment. A decade ago, high-dose chemotherapy was the standard. Today, we are shifting toward highly effective, less toxic targeted options, fundamentally altering how we approach AML inpatient care.

Finally, in lymphoma, immunotherapy also plays a central role. This year’s data focused on optimizing first-line treatments. Bispecific antibodies are being tested both in combination with standard R-CHOP and as standalone agents (e.g., toxin-conjugated antibodies). Phase II studies have shown promising results, and we eagerly await Phase III confirmations.

One truly practice-changing study presented in the plenary session compared Pola-R-GEMOX (which includes polatuzumab vedotin, a toxin-conjugated antibody) with the conventional R-GEMOX regimen in relapsed/refractory DLBCL. Previously, polatuzumab was approved based on a small Phase II study comparing it to BR (bendamustine-rituximab), which is not ideal for aggressive lymphomas. The new Phase III results are significant: CR rates increased by 20%, PFS improved by 15–20%, and overall survival showed marked gains. This could redefine the standard of care for DLBCL patients who are not eligible for CAR-T therapy.
 

So, my key takeaway is this: for your next patient with relapsed DLBCL, if CAR-T therapy is not feasible, Pola-R-GEMOX presents a highly effective alternative.

Thank you for your attention. Warm greetings from Milan and best wishes for a productive EHA 2025.

专家简介

Martin Dreyling教授

德国慕尼黑大学医院

德国慕尼黑大学医院（LMU Hospital）内三科的医学教授兼淋巴瘤项目负责人

主要研究方向为恶性转化的分子机制，尤其关注B细胞受体通路抑制剂及免疫治疗等创新治疗策略。

现任欧洲套细胞淋巴瘤网络（European MCL Network）协调人，曾任德国淋巴瘤联盟主席，并曾担任欧洲血液学会（EHA）执行董事会成员。